Danish drugmaker Novo Nordisk has reported a positive Phase 3 trial of a new weight-loss injection. The data provided was a sub-analysis of cagrilintide, and Novo Nordisk explained that because of the outcome, it would be moving the medicine into a dedicated Phase 3 clinical program later this year. Despite today's 2% gain in morning trading, U.S.-listed shares of Novo Nordisk remain down more than 30% year-to-date. Do you have a news tip for Investopedia reporters? Please email us at [email protected] Ta ...